IPF progressed whether antifibrotic doses were kept or cut

Design

Retrospective cohort study in two US data sources

Population

1,572 patients with IPF starting nintedanib or pirfenidone

Primary outcome

Progression (FVC decline ≥10%, hospital admission, transplant or death)

Effect

Registry, stopping vs full dose: HR 1.51 (95% CI 1.04–2.18); reduction HR 1.17 (0.90–1.52)

Using the US Pulmonary Fibrosis Foundation Registry (545 patients) and Duke health records (1,027 patients), this retrospective study tracked people with idiopathic pulmonary fibrosis after starting nintedanib or pirfenidone.

About 60% to 64% stayed on full dose. Progression, defined as a 10% fall in FVC, hospital admission, transplant or death, was common in all groups. In the registry, stopping treatment was associated with faster progression (HR 1.51, 95% CI 1.04–2.18), but dose reduction was not; in the health records cohort, neither reached significance.

Tolerability limits these drugs in practice. The data suggest that reducing the dose to keep a patient on treatment is a reasonable compromise, while stopping altogether may carry more risk. The study is observational and cannot settle either point.

• Expect many patients to need dose reduction for side effects.
• Consider reducing the dose before stopping an antifibrotic.
• Manage diarrhoea, nausea and photosensitivity actively to support adherence.
• Discuss transplant referral early where appropriate; progression was common on any dose.

Why it matters

Keeping patients on some antifibrotic may matter more than holding the full dose.

Don't overread it

Patients who stop may be sicker; this cannot show that stopping caused progression.

The statistics, in plain English

The registry hazard ratio of 1.51 for stopping means about 50% faster progression, with an interval just above 1. The second cohort did not confirm it, so the signal is uncertain.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.